AR059742A1 - Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol - Google Patents

Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol

Info

Publication number
AR059742A1
AR059742A1 ARP070100903A ARP070100903A AR059742A1 AR 059742 A1 AR059742 A1 AR 059742A1 AR P070100903 A ARP070100903 A AR P070100903A AR P070100903 A ARP070100903 A AR P070100903A AR 059742 A1 AR059742 A1 AR 059742A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulations
dihydroxifenil
anhydra
vinil
benzoxazol
Prior art date
Application number
ARP070100903A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475768&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059742A1 publication Critical patent/AR059742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente está dirigida a formulaciones farmacéuticas de una forma cristalina anhidra de un modulador de un receptor estrogénico, y composiciones farmacéuticas y procedimientos para la preparacion de éstas.
ARP070100903A 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol AR059742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77984806P 2006-03-06 2006-03-06

Publications (1)

Publication Number Publication Date
AR059742A1 true AR059742A1 (es) 2008-04-23

Family

ID=38475768

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100903A AR059742A1 (es) 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol

Country Status (5)

Country Link
US (1) US20070208069A1 (es)
AR (1) AR059742A1 (es)
PE (1) PE20080117A1 (es)
TW (1) TW200800179A (es)
WO (1) WO2007103873A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080146630A1 (en) * 2006-11-21 2008-06-19 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080139633A1 (en) * 2006-11-21 2008-06-12 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080176914A1 (en) * 2006-11-21 2008-07-24 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080132554A1 (en) * 2006-11-21 2008-06-05 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
SG10201508982TA (en) * 2010-11-01 2015-12-30 Melinta Therapeutics Inc Pharmaceutical compositions
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PREPARATION METHOD THEREOF
US20230255885A1 (en) * 2018-08-18 2023-08-17 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
EP3836898A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2022229361A1 (en) * 2021-04-29 2022-11-03 Solvay Specialty Polymers Italy S.P.A. Pvdf fine powders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437599A1 (de) * 1984-10-13 1986-04-17 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20060121111A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
GT200500349A (es) * 2004-12-02 2006-07-03 Formulaciones de benzoxazoles substituidos
JP2008521904A (ja) * 2004-12-02 2008-06-26 ワイス 置換ベンゾオキサゾールの製剤
AR052681A1 (es) * 2005-03-08 2007-03-28 Wyeth Corp Formas cristalinas de 2-(3-fluoro-4 hidroxifenil ) -7 -vinil-1,3- benzoxazol -5-ol
AR059574A1 (es) * 2006-02-14 2008-04-16 Wyeth Corp Formulaciones farmaceuticas acuosas de ligandos selectivos er-beta

Also Published As

Publication number Publication date
US20070208069A1 (en) 2007-09-06
WO2007103873A2 (en) 2007-09-13
WO2007103873A3 (en) 2007-12-06
PE20080117A1 (es) 2008-02-22
TW200800179A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
AR059742A1 (es) Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol
HN2007000407A (es) Compuesto de biaril eter urea
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
UY33075A (es) Derivados de ciclohexano y usos de los mismos
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
ECSP11011341A (es) Inhibidores de epoxicetona proteasa de tripéptidos cristalinos
AR075291A1 (es) Proceso para la preparcion de derivados de l-alanina protegidos
HN2010002582A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
CO6400230A2 (es) Conjugados de insulina cristalina
ECSP11011398A (es) Inhibidores de beta-secretasa
PA8717801A1 (es) Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
CL2011002657A1 (es) Proceso para preparar una mezcla racemica de acidos cis- y trans-octahidro ciclopenta[c]pirrol-1-carboxilicos; compuestos intermediarios.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
ECSP099565A (es) Compuesto de 2-amino pirimidina
EA201001243A1 (ru) Кристаллические формы n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамида и способы их получения
GT200800281A (es) Procedimiento para hacer sales de n-hidroxi-3-(4-(((2-(2-metil-1h-indol-3-il)-etil)amino)metil)fenil)-2e-2-propenamida
BRPI0809288A2 (pt) Formulações farmacêuticas auto-precipitação para a liberação modificada de um princípio ativo
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY33348A (es) Compuestos de furopiridina y usos de los mismos
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
ITPR20070098A1 (it) Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
GT200900215A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina.
GT200900037A (es) Compuestos organicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure